M. Jack Borrok

MedImmune (AstraZeneca)

Dr. Borrok joined Astrazeneca in 2010 and currently works on a variety of antibody technologies focusing on the IgG Fc including antibody half-life extension, modulating effector function, ADCs, targeted drug delivery, and improving antibody developability.  Jack received his PhD in biochemistry in 2007 from the University of Wisconsin-Madison and received post-doctoral training at The University of Texas at Austin, where he studied antibody & protease engineering, as well as the biology of the IgG Fc region.

Sessions